What Lifetech Scientific Co, Ltd does

Lifetech Scientific Co., Ltd (先健科技, HKG: 1302) is a Shenzhen-based, publicly listed Chinese medical device company founded in 1999 that develops, manufactures, and globally commercializes minimally invasive interventional devices for structural heart disease, peripheral vascular disease, and cardiac arrhythmia. Its portfolio spans four generations of congenital heart disease occluders (HeartR, Cera, CeraFlex, Absnow), the LAmbre family of left atrial appendage occluders with approximately 40,000 cumulative clinical cases across roughly 40 countries, and a comprehensive aortic endovascular franchise including the G-Branch thoracoabdominal hybrid multi-branch stent graft, G-iliac bifurcated system, Ankura and Yuranos thoracic/abdominal stent grafts, Fitaya vena cava filter, Futhrough fenestration system, and Fustar steerable sheath.

The company's core proprietary technology platform is IBS (Iron-Based Bioresorbable Scaffold), positioned as the world's first iron-based fully bioresorbable stent platform, with coronary, pediatric pulmonary (IBS Angel), and peripheral (IBS Titan) products in clinical development, and is supported by 2,631 cumulative global patent applications as of December 31, 2025 and a 22nd China Patent Gold Award for LAmbre. Lifetech led development of ISO 22679:2021, the first international standard for transcatheter cardiac occluders, and has placed 17 products in the NMPA Innovation Medical Device Green Channel.

The business operates a hybrid GTM combining direct global sales through 7 overseas subsidiaries across approximately 120 countries and event-driven academic engagement at major international conferences (CAFS, CSI, LINC, CEC, TCT, AEPC, VEC). Revenue is generated primarily through hardware sales to hospitals and cardiac/vascular surgery centers across three segments: structural heart disease (RMB 527.6 million in 2024, 6.4% YoY growth), peripheral vascular disease (RMB 751.1 million in 2024, 6.2% YoY growth), and pacemaker/electrophysiology products (RMB 25.0 million in 2024, including HeartTone pacemakers co-developed with Medtronic). FY2025 revenue reached RMB 1,369.8 million (+5.1% YoY) with 74.4% gross margin, RMB 353.4 million adjusted net profit (+24.9%), RMB 719.3 million cash reserves, and R&D investment of approximately 23% of revenue. International business represented 26.6% of FY2024 revenue, with Europe growing 25.9% in 2025 and Asia ex-China growing 33.6% in 2024. The company is now actively building a cardiac electrophysiology platform through 2025-2026 strategic investments in Yuanshan Medical (PFA), Jianhu Medical (30% equity), and Affector Medtech (22.22% equity), alongside the Starway Medical Technology acquisition announced in 2026.

Name

Lifetech Scientific Co, Ltd

Legal name

先健科技（深圳）有限公司

Website

https://lifetechmed.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Lifetech Scientific (先健科技, HKG: 1302) is a Shenzhen-based medical device company developing minimally invasive interventional implants for structural heart disease, peripheral vascular disease, and cardiac arrhythmia, serving hospitals and cardiac centers in approximately 120 countries.

Ownership category

akta.pro rank

Product category

Interventional Cardiovascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH)

akta.pro secondary industries

Endovascular Aortic Repair (EVAR/TEVAR) & Aortic Grafts (HLAHAFAF), Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE), Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL), Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)

Keywords

• Cardiovascular medical devices
• Interventional medical devices
• Peripheral vascular stents
• Structural heart devices
• Bioresorbable implants

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Structural Heart Disease Products: Revenue from congenital heart disease occluders (HeartR, Cera, CeraFlex) and LAmbre left atrial appendage occluder systems. Structural heart disease contributed RMB 527.6 million in 2024 (6.4% YoY growth), driven by LAmbre with 12.4% YoY growth. LAmbre maintains #1 domestic market share among domestic brands globally.
2. Peripheral Vascular Disease Products: Revenue from aortic stent grafts (thoracic and abdominal), iliac bifurcated stents, and vena cava filters. Contributed RMB 751.1 million in 2024 (6.2% YoY growth). Stent graft sales grew 19.9% driving overall 5.1% revenue growth in 2025 to RMB 1,369.8 million.
3. Pacemaker Electrophysiology Products: Revenue from HeartTone implantable cardiac pacemakers and related leads produced in partnership with Medtronic. Contributed RMB 25.0 million in 2024. MRI-compatible pacemaker system under development with Medtronic.
4. Electrophysiology Distribution Rights: Revenue from exclusive overseas distribution of electrophysiology products (PFA systems from Yuanshan Medical) as part of strategic expansion into cardiac electrophysiology market.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Lifetech Scientific designs, manufactures, and sells minimally invasive interventional medical devices for cardiovascular and peripheral vascular applications, with three core solution areas: structural heart disease (occluders for congenital defects and left atrial appendage closure), peripheral vascular disease (aortic stent grafts, iliac bifurcation stents, vena cava filters, and fenestration systems), and cardiac arrhythmia (pacemakers, PFA ablation systems, and 3D cardiac mapping). The company pioneered the world's first iron-based bioresorbable stent platform and the first TAAA hybrid multi-branch stent graft for complete endovascular visceral branch reconstruction.

Product overview

Lifetech Scientific Co, Ltd is a leading cardiovascular and peripheral vascular interventional medical device company offering a comprehensive portfolio of innovative products across three main solution areas: Structural Heart Disease Solutions (including left atrial appendage occluders, congenital heart disease occluders, and bioresorbable stents), Peripheral Vascular Disease Solutions (including aortic stent grafts, iliac artery systems, and thrombosis management devices), and Cardiac Arrhythmia Solutions (including pacemakers, PFA systems, and 3D mapping systems). The company has developed the world's first iron-based bioresorbable material platform and pioneered multiple groundbreaking devices including the G-Branch thoracoabdominal stent graft system, LAmbre left atrial appendage occluder, and CS aortic arch three-branch reconstruction system. Their product portfolio encompasses over 20 major product categories with four generations of congenital heart disease occluders, multiple aortic stent graft systems, and emerging electrophysiology solutions.

Differentiator

Problem solved

Functional benefit

Brands

• LAmbre: Left atrial appendage occluder system - China's first domestically developed LAA occluder with global applications in nearly 40 countries with nearly 40,000 clinical cases.
• LAxible
• LAnavi
• G-Branch
• G-iliac
• IBS
• Ankura
• HeartTone
• Yuranos
• Fitaya
• Cera/CeraFlex
• KONAR-MF
• Fustar
• Futhrough

Products and services

• LAmbre Left Atrial Appendage Occluder System Left atrial appendage occluder with dual-disc design for stroke prevention in non-valvular atrial fibrillation patients. Features unique anchoring mechanism and extensive size range covering various left atrial appendage anatomies. China's first domestically developed LAA occluder with global deployment.
• LAxible Next-Generation Left Atrial Appendage Occluder Next-generation left atrial appendage occluder with optimized design including integrated fixed disc suture and fully coated flow-blocking membrane for improved stability and reduced complications in atrial fibrillation stroke prevention.
• Congenital Heart Disease Occluder Series (HeartR, Cera, CeraFlex, Absnow, KONAR-MF) Comprehensive portfolio of occluders for atrial septal defect (ASD), ventricular septal defect (VSD), and patent ductus arteriosus (PDA) treatment including HeartR (1st gen), Cera (2nd gen nano-titanium coating), CeraFlex (3rd gen rotatable), Absnow (4th gen bioresorbable), and KONAR-MF multi-functional occluder. National Manufacturing Single Champion recognized product.
• G-Branch Thoracoabdominal Aortic Stent Graft System Globally pioneering thoracoabdominal aortic stent graft system with 2 internal and 2 external branches for complete endovascular visceral branch reconstruction in thoracoabdominal aortic aneurysm (TAAA) treatment. World's first TAAA hybrid multi-branch stent graft.
• G-iliac Iliac Artery Bifurcated Stent Graft System First domestic iliac bifurcated stent graft system for endovascular iliac artery reconstruction ensuring internal iliac artery preservation during EVAR procedures. Demonstrated 97.3% patency rate in clinical studies.
• Ankura Thoracic Aortic Stent Graft System Full-range thoracic aortic stent graft system with asymmetric waveform design and excellent flexibility for various aortic pathologies. Includes Ankura Pro and Ankura Plus variants with in-situ fenestration capability for branch vessel reconstruction.
• CS Concave Supra-Arch Three-Branch Reconstruction System Global pioneering concave supra-arch aortic branched stent graft system with unique concave mid-body open structure for complete three-branch endovascular reconstruction without cerebral ischemia risk. Enables aortic arch reconstruction in as short as 29 minutes with zero permanent paraplegia demonstrated in clinical studies.
• Yuranos Abdominal Aortic Stent Graft System Next-generation abdominal aortic stent graft with optimized waveform structure and enhanced flexibility for complex aortic aneurysm anatomies.
• Fitaya Inferior Vena Cava Filter System Next-generation inferior vena cava filter with 60-day retrieval window (longest among spindle-shaped filters) for deep vein thrombosis prevention.
• HeartTone Implantable Cardiac Pacemaker Series MRI-compatible implantable cardiac pacemaker system developed in collaboration with Medtronic for treatment of bradycardia. China's first domestically produced fully automated pacemaker system providing complete pacing solution with supporting electrodes and programmer.
• Pulsed Field Ablation (PFA) System Pulsed Field Ablation system using irreversible electroporation technology for treatment of drug-refractory atrial fibrillation. Developed in partnership with Yuanshan Medical.
• StarTrek 3D Cardiac Electrophysiology Mapping System 3D electrophysiology mapping system using proprietary dielectric 3D mapping technology for cardiac ablation procedures. Developed in partnership with Jianhu Medical.
• IBS Iron-Based Bioresorbable Coronary Stent System Global pioneering iron-based bioresorbable drug-eluting coronary stent with ultra-thin struts (70-80μm) that degrades completely within 2 years, eliminating long-term implant risks. World-first iron-based fully biodegradable stent technology.
• IBS Angel Iron-Based Bioresorbable Pediatric Pulmonary Stent World's first iron-based bioresorbable stent designed for pediatric pulmonary artery applications, providing temporary support that fully degrades as vessel matures. FDA Compassionate Use approved for US patient treatment.
• IBS Titan Iron-Based Bioresorbable Peripheral Stent Iron-based bioresorbable drug-eluting peripheral stent system for below-the-knee applications in peripheral vascular disease treatment.
• Peripheral Thrombosis Aspiration Catheter System First domestic OTW (over-the-wire) dual-lumen peripheral thrombosis aspiration catheter for efficient thrombus removal in peripheral arteries, veins, and filters.
• G-iliac Pro Iliac Artery Covered Stent System Next-generation iliac artery covered stent system with enhanced precision for internal iliac artery reconstruction during endovascular aneurysm repair.
• LAmbre Plus Left Atrial Appendage Occluder System Enhanced left atrial appendage occluder with optimized structure for improved safety and effectiveness. Currently undergoing US FDA pre-market clinical trial with Medicare coverage for approximately 1,500 paid implantations planned at up to 75 US centers.

Quantifiable outcome

• G-Branch achieved 100% technical success rate and 0% aneurysm-related mortality in FIM study (15 patients, 12-month follow-up)
• +4 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Yuanshan Medical (远山医疗科技有限责任公司)coreStrategic or Co-development Partner · 4 February 2026Strategic cooperation for PFA (Pulsed Field Ablation) technology global development and commercialization. Lifetech will serve as exclusive overseas distributor for Yuanshan's PFA system and related products. Yuanshan's PFA system received NMPA approval in April 2025 for drug-refractory recurrent paroxysmal atrial fibrillation treatment. Partnership leverages Lifetech's global sales network and Yuanshan's leading PFA technology for mutual market expansion.
• Jianhu Medical (剑虎医疗科技(苏州)有限公司)coreStrategic or Co-development Partner · 6 June 2025Strategic partnership in cardiac electrophysiology. Lifetech will invest RMB 150 million in phases for 30% equity stake in Jianhu Medical. Jianhu's StarTrek 3D mapping system received NMPA approval in May 2025. Lifetech gains exclusive overseas distribution rights for Jianhu's electrophysiology products including 3D mapping equipment, circular mapping catheters, high-density mapping catheters, RF and PFA ablation systems. Partnership enables comprehensive cardiac electrophysiology solution offering.
• Affector Medtech (Suzhou) Ltd. (苏州溢科来医疗科技有限公司)coreStrategic or Co-development Partner · 31 March 2025Strategic investment of RMB 150 million in two stages to acquire 22.22% equity and exclusive overseas distribution rights for electrophysiology products. First stage completed. Entry into cardiac electrophysiology market through this investment, providing additional growth momentum and product pipeline expansion.
• European Association for Pediatric Cardiology (AEPC)minorStrategic or Co-development Partner · 20 July 2022Collaboration with AEPC for European pediatric congenital heart disease interventional training. Three-day training workshop held at German Heart Center Munich with Prof. Eicken, Prof. Boekenkamp, and Prof. Krasemann as instructors. Training used CeraFlex and KONAR-MF occluders for ASD, VSD, and PFO interventional treatment. Part of broader academic exchange and international training collaboration.
• National Cardiovascular Center Fuwai Hospital / Prof. Shu Chang (国家心血管病中心/阜外医院舒畅教授)coreStrategic or Co-development Partner · 20 May 2022Joint development of CS concave supra-arch branched stent-graft system. 10-year R&D collaboration producing global first aortic arch three-branch reconstruction solution. FIM clinical study completed. Product entered NMPA Green Channel in January 2026. Also co-developed in-situ fenestration branch reconstruction product matrix including Ankura Plus and CSkirt products.
• Medtronic (美敦力公司)coreStrategic or Co-development Partner · 16 December 2021Expanded strategic cooperation for domestic pacemaker project. Extended HeartTone pacemaker cooperation to 2028. New cooperation for MRI-compatible pacemaker system development. Medtronic provides technical consultation and waived royalty fees for specific products. Partnership began in 2014. HeartTone pacemaker launched in December 2017 as first fully automated domestic pacemaker system. New MRI-compatible system will fill domestic gap in this field.
• Peking Union Medical College Hospital / Prof. Guo Wei (解放军总医院郭伟教授)coreStrategic or Co-development Partner · 1 October 2019Joint development of G-Branch TAAA hybrid multi-branch stent graft system. Prof. Guo Wei as lead PI for FIM study and GUARANTEE registration trial. G-Branch received NMPA approval in November 2025. Product represents breakthrough in visceral branch reconstruction and won multiple international innovation awards.
• ABG Innovation-Quantum Limited / Quantum Surgical SASminorStrategic or Co-development Partner · 1 January 2019Joint venture Dongguan Lifetech Quantum Medical Technology Co., Ltd. established in 2019 for tumor intervention robotics R&D and commercialization. Innovative surgical robot completed type inspection and submitted China registration application in 2021, currently under regulatory review. Entry into tumor intervention segment through this collaboration.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Cook Medical: Private global medical device company with strong peripheral vascular, aortic intervention (Zenith TX2/TAA), and vena cava filter (Celect) portfolios. Competes with Lifetech's Fitaya, Ankura, and iliac/atherectomy product lines globally.
• Boston Scientific Corporation: Major global interventional cardiology, structural heart (Watchman FLX LAA closure), peripheral vascular, and electrophysiology player. Competes with Lifetech in LAA closure globally and in peripheral vascular intervention, and represents a benchmark for the cardiovascular franchise Lifetech is building.
• Abbott Laboratories: Major global cardiovascular device player with competing structural heart (Amplatzer occluders), peripheral vascular, and cardiac rhythm management portfolios. Direct LAmbre competitor in LAA closure with Amplatzer Amulet and in aortic intervention with Trevo/Graftmaster franchises.
• W. L. Gore & Associates: Private global leader in endovascular aortic repair (GORE EXCLUDER, TAG thoracic endograft) and vascular grafts. Direct competitor to Lifetech's Ankura, Yuranos, and G-Branch aortic stent graft systems in the global thoracoabdominal and thoracic aortic markets.
• Edwards Lifesciences: Global structural heart leader (TAVR/SAPIEN) and critical care monitoring company. Competes in structural heart and is a benchmark for premium structural heart device economics relevant to Lifetech's LAA and CHD occluder franchises.
• Medtronic plc: Global leader in cardiac rhythm management (pacemakers), structural heart, and aortic/peripheral vascular intervention. Strategic partner to Lifetech for HeartTone pacemakers since 2014, and competitor in structural heart and aortic endovascular markets globally.

Direct peers

• MicroPort Scientific Corporation: Hong Kong-listed Chinese cardiovascular and orthopedic medical device company with overlapping structural heart (left atrial appendage occluder), peripheral vascular, and electrophysiology product portfolios. Most directly comparable peer given similar China-origin, cardiovascular-focused, publicly-traded profile and competing aortic/structural heart franchises.
• Lepu Medical Technology: Beijing-based Chinese medical device company with strong cardiovascular interventional portfolio including stents, occluders, and structural heart devices. Competes with Lifetech in China's congenital heart disease occluder market and shares the same hospital procurement and VBP exposure.

Regional players

• Terumo Corporation: Japanese global medical device company with interventional systems and access products, including peripheral vascular and structural heart franchises that overlap with Lifetech's portfolio. Comparable as a publicly-traded Asia-headquartered cardiovascular device peer with global distribution.

Emerging players

• Penumbra, Inc. US-based vascular thrombectomy and peripheral vascular intervention company with the Indigo aspiration system that competes with Lifetech's peripheral thrombosis aspiration catheter. Comparable mid-cap growth profile in peripheral vascular intervention.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/lifetech-scientific-inc-

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lifetech Scientific Co, Ltd